Showing results (241-250 of 2,864) with videos related to

Sort By:
Pageof 287
JACC. Cardiovascular Interventions|May 20, 2017
Safety and Efficacy of Transcatheter Aortic Valve Replacement in the Treatment of Pure Aortic Regurgitation in Native Valves and Failing Surgical Bioprostheses: Results From an International Registry StudyFadi J Sawaya, Marcus-André Deutsch, Moritz Seiffert, et al.
JACC. Cardiovascular Interventions|May 22, 2017
Randomized Comparison of Absorb Bioresorbable Vascular Scaffold and Mirage Microfiber Sirolimus-Eluting Scaffold Using Multimodality ImagingErhan Tenekecioglu, Patrick W Serruys, Yoshinobu Onuma, et al.
JACC. Cardiovascular Interventions|May 22, 2017
Prevalence, Management, and Long-Term (6-Year) Outcomes of Atrial Fibrillation Among Patients Receiving Drug-Eluting Coronary StentsHyo-In Choi, Jung-Min Ahn, Se Hun Kang, et al.
JACC. Cardiovascular Interventions|May 22, 2017
Outcomes in Patients Undergoing Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction Via Radial Access Anticoagulated With Bivalirudin Versus Heparin: A Report From the National Cardiovascular Data RegistryIon S Jovin, Rachit M Shah, Dhavalkumar B Patel, et al.
JACC. Cardiovascular Interventions|June 6, 2017
Biodegradable Polymer Biolimus-Eluting Stents Versus Durable Polymer Everolimus-Eluting Stents in Patients With Coronary Artery Disease: Final 5-Year Report From the COMPARE II Trial (Abluminal Biodegradable Polymer Biolimus-Eluting Stent Versus Durable Polymer Everolimus-Eluting Stent)Georgios J Vlachojannis, Pieter C Smits, Sjoerd H Hofma, et al.
JACC. Cardiovascular Interventions|June 24, 2017
Dual Antiplatelet Therapy for 6 Versus 18 Months After Biodegradable Polymer Drug-Eluting Stent ImplantationMasato Nakamura, Raisuke Iijima, Junya Ako, et al.
JACC. Cardiovascular Interventions|June 24, 2017
Long-Term Clinical Outcomes of Patients Treated With Everolimus-Eluting Bioresorbable Stents in Routine Practice: 2-Year Results of the ISAR-ABSORB RegistryJens Wiebe, Petra Hoppmann, Roisin Colleran, et al.
JACC. Cardiovascular Interventions|February 5, 2010
Long-term clinical and economic analysis of the Endeavor zotarolimus-eluting stent versus the cypher sirolimus-eluting stent: 3-year results from the ENDEAVOR III trial (Randomized Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions)Eric L Eisenstein, Martin B Leon, David E Kandzari, et al.
JACC. Cardiovascular Interventions|February 5, 2010
Safety and effectiveness of the Endeavor zotarolimus-eluting stent in real-world clinical practice: 12-month data from the E-Five registryChaim Lotan, Ian T Meredith, Laura Mauri, et al.
JACC. Cardiovascular Interventions|February 5, 2010
3-Dimensional bifurcation angle analysis in patients with left main disease: a substudy of the SYNTAX trial (SYNergy Between Percutaneous Coronary Intervention with TAXus and Cardiac Surgery)Chrysafios Girasis, Patrick W Serruys, Yoshinobu Onuma, et al.
Pageof 287